

Anti Diabetic and Hypolipidemic Activity of Bark of Ethanolic Extract of *Ougeinia Oojeinensis* (ROXB.)

C Velmurugan, M.Pharm*, T Sundaram, M.Pharm**, R Sampath Kumar, PhD***, B Vivek, M.Pharm*, D SheshadriShekar, PhD*, B S Ashok Kumar, M.Pharm****

*Department of Pharmacology, Sri K.V College of Pharmacy, M.G.Road, Chickballapur-562101, *Department of Pharmaceutics, Sri K.V College of Pharmacy, M.G.Road, Chickballapur-562101, ***Department of Pharmaceutics, JKK Nataraja College of Pharmacy, Komarapalayam-638183, ****Department of Pharmacognosy, Sri K.V College of Pharmacy, M.G.Road, Chickballapur-562101

SUMMARY

The hypoglycemic and hypolipidemic effect of Ethanolic extract of *Ougeinia oojeinensis* (200mg/kg) bark was evaluated with measurements including, Body weight, blood glucose level, urine glucose and biochemical parameters. The ethanolic extracts of the powdered bark was tested for its efficacy in alloxan-induced diabetic rats. Animals were induced for diabetes with Alloxan (150 mg/kg of body weight- i.p.) and treated orally with Ethanolic extract of *Ougeinia oojeinensis*. The extracts were also evaluated for acute oral toxicity studies and its effect on different biochemical parameters. The extracts showed significant ($p < 0.01$) antihyperglycemic and hypolipidemic activity as compared to diabetic control. The extract shows beneficial effects on blood glucose and urine glucose level. It also reduces the elevated biochemical parameters such as triglycerides (TGL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), Total Cholesterol (TC) and increased the reduced level of high density lipoprotein (HDL) and body weight, which might be due to presence of steroids, tannins, alkaloids and triterpenoids present in that extract. Thus ethanolic extract could serve as good oral hypoglycemic agents and seems to be promising for the development of phytomedicines for diabetes mellitus.

KEY WORDS:

Ougeinia oojeinensis, Anti diabetic activity, Plasma glucose level Alloxan induced diabetic rats

INTRODUCTION

According to WHO, the prevalence of diabetes is likely to increase by 35% by the year 2025. Currently there are over 150 million diabetics worldwide and this is likely to increase to 300 million or more. Statistical projection about India suggests that the number of diabetics will rise from 15 million in 1995 to 79.4 million by 2025, making it the country with the highest number of diabetics in the world^{1,2}. Diabetes is a serious metabolic, disorder with micro and macrovascular complication that results in significant morbidity and mortality³. Chronic hyperglycemia during diabetes causes glycation of body proteins that in turn leads to secondary complications affecting eyes, kidneys, nerves and arteries⁴. Modern medicines like biguanides, sulphonylureas and thiazolidinediones are available for the treatment of diabetes.

But they also have undesired effects associated with their uses⁵. Alternative medicines particularly herbal medicines are available for the treatment of diabetes. Common advantages of herbal medicines are effectiveness, safety, affordability and acceptability⁶. Medicinal plants and their products have been used in the Indian traditional system of medicine and have shown experimental or clinical anti-diabetic activity^{7,8}. Medicinal Plants are a rich source of natural products. Medicinal plants and their products have been widely used for treatment of diabetic populace all around the world with less known scientific basis of their functioning^{9,10}. Hence, natural products from medicinal plants need to be investigated by scientific methods for their anti-diabetic activity. The plant *Ougeinia oojeinensis* (Roxb.) belonging to family Fabaceae and commonly known as Atimukta in Sanskrit, Tinis in Bengali, Tinisha in Hindi, Narivengayam in Tamil, Bhinoharmo in Gujarati, Karimutale in Kannada, Malavenna in Malayalam, Tiwas in Marathi, Sandan pipli in Nepali and Tellamotuka in Telugu¹¹. The ayurvedic formulation Tinisha clinically used for burning syndrome, skin disease, urinary disorder, obesity, anti inflammatory¹², anti spasmodic, and anti hypertensive activity. As per the literature review the plant having hypoglycemic and hypolipidemic property¹¹, which is not scientifically documented. In the present study, we reported hypoglycemic and hypolipidemic potentials of *Ougeinia oojeinensis* (Roxb.) in diabetic rat model.

MATERIALS AND METHODS

Taxonomical identification:

The bark of *Ougeinia oojeinensis* was collected and identified.

Preparation of extracts

The collected bark was shade dried completely. The dried bark was then coarsely powdered and was sieved (sieve # 60) to get uniform coarse powdered. The extract was prepared by continuous hot extraction using ethanol as a solvent. Extracts obtained was concentrated, dried kept in a desiccator for further use. The yield was found to be 14.50%w/w.

Preliminary phytochemical screening

The Ethanolic extract of *Ougeinia oojeinensis* was screened for the presence of various phytoconstituents like steroids, alkaloids, flavonoids, saponin, mucilage, tannin and phenolic compounds¹³.

This article was accepted: 15 March 2011

Corresponding Author: Velmurugan C Chinnu, Department of Pharmacology, Sri. K.V.College of pharmacy, Chickaballapur, Karnataka, 562101

Email: velu0906@gmail.com

Experimental Animals

All the experiments were carried out using male, Swiss Albino mice (25-30 g) and Wister rats (150-200 g) procured from the animal house, IRT Perundurairi medical college, Erode, Tamilnadu, India. On arrival the animals were placed at random and allocated to treatment groups in polypropylene cages with paddy husk as bedding. Animals were housed at a temperature of $24 \pm 2^{\circ}\text{C}$ and relative humidity of 30–70%. A 12:12 light: day cycle was followed. All animals were allowed free access to water and fed with standard commercial rat chaw pellets (M/s. Hindustan Lever Ltd, Mumbai). The animal experimental protocol was approved by Institutional Animal Ethical Committee as per the guidance of the Committee for the Purpose of Control and Supervision of Experiments on Animals (688/2/C-CPCSEA)

Acute oral toxicity studies

The acute toxicity study was carried out as per OECD 425 Guidelines. Mortality in each group within 24 h was recorded. The animals were observed for a further 14 days for any signs for delayed toxicity. The Ethanollic extract of *Ougeinia oojeinensis* had good margin of safety and did not shown any lethal effects on the animals up to the doses of 2000mg/kg. Hence the LD50 of *Ougeinia oojeinensis* was considered as 2000mg/kg. Studies were carried out with 1/10 of the LD50 as therapeutic dose (200mg/kg).

Anti-diabetic study¹⁴⁻²⁰

In the experiment a total of 24 overnight fasted rats were used. The 18 rats were rendered diabetic by the intraperitoneal injection of alloxan (150 mg/kg). 48hrs after alloxan injection, the animals which did not developed hyperglycemia i.e. glucose level > 200mg/dl, were rejected and replaced with new animals. Immediately after confirmation of diabetes, rats were classified into four groups of six rats each. Evaluation of antidiabetic effect of test extracts was done by taking six rats in each groups as: Group I served as normal control (saline); Group II served as diabetic control (alloxan induced);

Group III received ethanollic extract (200mg/kg) and Group IV served as reference standards (Glibenclamide, 3 mg/kg). Treatment was continued for 14 consecutive days, with once a day dose. Before the treatment (0 day) and at the end of 5th, 10th and 14th day, blood samples were collected from the retro orbital vein of each rat under mild ether anesthesia and serum separated by centrifugation of blood at 4000 rpm for 10mins. Samples were subjected to glucose measurement using a semi auto analyzer. Urine glucose level was estimated on 0 day and 14th day by Benedict's test. Estimation of biochemical parameters were done with 1ml of blood withdrawn on 14th day, from all four groups of rats (normal, diabetic control, extracts and standard treated) under mild anesthesia, where serum was separated by centrifugation of sample at 4000 rpm for 10min and stored in a refrigerator until analyzed. And the serum was subjected for the estimation of TGL, HDL, LDL, VLDL and TC by a semi auto analyzer.

The percentage reduction /increased glucose concentration and biochemical parameters was calculated by the following formula

Diabetic control-test
-----x 100
Diabetic control

STATISTICAL ANALYSIS

One-way analysis of variance (Anova) followed by Dunnett's method of multiple comparisons was employed using Graphpad Instat 3.0 software. A probability value of $p < 0.01$ was considered to be statistically significant.

RESULTS

Preliminary phytochemical screening

The preliminary phytochemical analysis of Ethanollic Extract of *Ougeinia Oojeinensis* shows presence of flavonoids, saponins, alkaloids, Mucilage, tannins and phenolic compounds.

Acute toxicity

Acute oral toxicity studies following OECD guidelines-425, up and down procedure, showed that ethanollic extracts upto 2000mg/kg are non-toxic and safe.

Blood glucose level

The standard (glibenclamide 3mg/kg) and ethanollic extract (200mg/kg) treated groups, the peak values of blood sugar significantly decreased to 128 mg/dl (60.89%) and 84.17 mg/dl (74.28%) simultaneously on the 14th day (Figure 1&2). Thus, the ethanollic extract was found to be more significant ($p < 0.01$) as standard drug in lowering blood glucose level compare to diabetic control.

Body weight and urine glucose

The Figure 3 shows the body weight of the normal and treated groups significantly differ from diabetic control on 14th day. In the same way urine glucose level of normal and treated groups also significantly differ from diabetic control on 14th day shown in Table I.

Biochemical parameters

Figure 4 shows ethanollic extracts has significantly reversed the diabetes-induced hyperlipidemia Compared to diabetic control. A significant percentage reduction of total cholesterol level (59.91%), LDL (64.85%), TGL (22.58%) and VLDL (22.36%) in ethanollic extract treated was comparative to standard drug treated groups, total cholesterol (66.55%), LDL (79.50%), TGL (26.68%) and VLDL (26.57%) and reached normal value. However, the HDL level increased with treatment of extract and GLB group respectively. Figure 5 shows increased HDL level by extract and GLB.

Table I: Effect of oral administration of the ethanollic extract of *Ougeinia Oojeinensis* (Roxb.) on urine sugar in severe diabetic rats

Group	Urine sugar	
	0 day	14 day
Normal control	-	-
Diabetic control	+++	+++
Ethanollic extract	+++	+
Glibenclamide	+++	+

(Trace = +, significantly = +++, Nil = -)




Fig. 1: Data for Blood glucose level of Ethanolic Extract of *Ougenina Oojeinensis* (Roxb.)




Fig. 2: Percentage reduction of blood glucose level by *Ougenina Oojeinensis* (Roxb.) on 14th day




Fig. 3: Data for Body Weight of Ethanolic Extract Of *Ougenina Oojeinensis* (Roxb.)




Fig. 4: Effect of ethanolic extracts of bark of *Ougenina Oojeinensis* (Roxb.) on Biochemical parameters




Fig. 5: Effect of ethanolic extracts of bark of *Ougenina Oojeinensis* (Roxb.) on Biochemical parameters

DISCUSSION

The present study was undertaken to investigate the anti-diabetic and hypolipidemic effects of *Ougenina Oojeinensis* (Roxb.) in a diabetic rat model. Glibenclamide was used as a standard drug. It is well established that glibenclamide (a long lasting sulfonylurea) acts mainly by stimulating insulin secretion. Alloxan is widely used to induce diabetes in experimental animals. The mechanism of action in β -cells of the pancreas has been intensively investigated and now is quite well understood. The cytotoxic action of alloxan is mediated by reactive oxygen species. Alloxan and the product of its reduction, dialuric acid, establish a redox cycle with the formation of superoxide radicals. These radicals undergo dismutation to hydrogen peroxide. Thereafter highly reactive hydroxyl radicals are formed by Fenton reaction. The actions of reactive oxygen species with a simultaneous massive increase in cytosolic calcium concentration cause rapid destruction of β -cells and thus

increase the blood sugar^{21,22}. The Earlier studies reported, that saponin and combination of saponins showed significant antidiabetic activity^{23,24}. There are reports that some plants contains mucilages and minerals like calcium, zinc, magnesium, manganese and copper had remarkable hypoglycaemic activity decreasing the blood glucose levels in diabetic rats within 15days^{25,26}. In the present study indicated that daily administration of *Ougeinia Oojeinensis* (200 mg/kg) up to 14 days showed anti-diabetic and hypolipidemic effects in diabetic rats. In a diabetic model rat, an increase in blood and urine sugar levels in diabetic rats was prevented by *Ougeinia Oojeinensis* (200 mg/kg). The effects were comparable to the standard drug glibenclamide. The majority of the experiments confirmed the benefits of medicinal plants with hypoglycaemic effects in the management of diabetes mellitus.

Numerous mechanisms of actions have been proposed for these plant extracts. Some hypotheses relate to their effects on the activity of pancreatic β cells (synthesis, release, cell regeneration/revitalization) or the increase in the protective/inhibitory effect against insulinase and the increase of the insulin sensitivity or the insulin-like activity of the plant extracts. Other mechanisms may involve improved glucose homeostasis (increase of peripheral utilization of glucose, increase of synthesis of hepatic glycogen and/or decrease of glycogenolysis acting on enzymes, inhibition of intestinal glucose absorption, reduction of glycaemic index of carbohydrates, reduction of the effect of glutathione. All of these actions may be responsible for the reduction and or abolition of diabetic complications. The saponins will reduce the level of serum glucose levels, liver phosphorylase and glucose-6-phosphatase activities, and significantly increased the serum pyruvate level and liver glycogen. There was also marked improvement in glucose utilization in diabetic rats. Serum insulin and pancreatic cAMP levels showed significant increases in diabetic rats²³. The accumulating evidences suggest that anti-hyperglycemic action of *Ougeinia Oojeinensis* might be involved in both pancreatic and extra pancreatic mechanisms.

Since, lipid abnormalities accompanying with atherosclerosis is the major cause of cardiovascular disease in diabetes. Therefore ideal treatment of diabetes, in addition to glycemic control, should have a favorable effect on lipid profiles. High level of TC and LDL are major coronary risk factors²⁷. Further, the studies suggested that TG itself is independently related to coronary heart disease^{28,29}. The abnormalities in lipid metabolism lead to elevation in the levels of serum lipid and lipoprotein that in turn play an important role in occurrence of premature and severe atherosclerosis, which affects patients with diabetes³⁰. Hence, measurements of biochemical parameters are necessary to prevent cardiac complications in diabetes condition. In this study, *Ougeinia Oojeinensis* (200 mg/kg) showed significant reduction in TC, TG, LDL, VLDL levels and increased level of HDL in diabetic model rats. However, the increased HDL (cardioprotective lipid) level by *Ougeinia Oojeinensis* was comparable to the standard drug glibenclamide. Therefore, *Ougeinia Oojeinensis* has potential role to prevent formation of atherosclerosis and coronary heart disease. Several authors reported that secondary metabolites, such as saponins,

flavonoids, phenolic compounds, and triterpenoids, have hypolipidemic activity³¹⁻³³. Hence, the hypolipidemic properties of *Ougeinia Oojeinensis* may be due to different types of active secondary metabolites, each with a single or diverse range of biological activities.

CONCLUSION

The present study demonstrated that ethanol extract of *Ougeinia Oojeinensis* could be useful in management of diabetes associated with abnormalities in lipid profiles. Further study need to be isolate, identify the active compounds and formulation.

REFERENCES

1. King H, Aubert RE. and Herman WH. Global burden of diabetes 1995-2025: prevalence, Numerical estimates and projections. *Diabetes Care*. 21, 1998; 1414- 31.
2. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H. Thompson TJ. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the US. *Diabetes Care*, 24, 2001; 1936-40.
3. Rang HP, Dale MM and Ritter JM. The Endocrine pancreas and the control of blood glucose. In:Barbara simmons, Susan Beasley. Eds. *Pharmacology*, 3rd edition, U.K., LongmanGroup Ltd., 1991; 403-10.
4. Sharma AK. *Diabetes Mellitus and its complications: An update*. 1st ed. Macmillan, New Delhi, 1993.
5. Fowler MJ. *Diabetes Treatment, Part 2: Oral agents for glycemic management*. *Clin Diabetes* 2007; 25: 131-34.
6. Valiathan MS. *Healing plants*. *Curr Sci* 1998; 75: 1122.
7. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. *J Ethnopharmacol* 2002; 81: 81-100.
8. Dineshkumar B, Mitra A, Manjunatha M. In vitro and in vivo studies of antidiabetic Indian medicinal plants: A review. *J Herbal Med Toxicol* 2009; 3: 9-14.
9. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. *Curr Sci* 2004; 86: 789-99.
10. Said O, Fulder S, Khalil K, Azaizeh H, Kassis E, Saad B. Maintaining a physiological blood glucose level with 'Glucoselevel', a combination of four antidiabetes plants in the traditional Arab herbal medicine. *Evid Based Complement Alternat Med* 2007; 5: 421-28.
11. Khare CP. *Indian herbal remedies rational western therapy, ayurvedic and traditional usage, botany*. Springer publications, Germany 2004; 343.
12. Ram Kumar Sahu, Devendra Dewangan, Amit Roy KP, Namdev. Antiinflammatory Action of *Ougeinia oojeinensis* (Roxb.) Hochr. Bark by HRBC Membrane Stabilization. *RJPT* 2008; 1: 57-58.
13. Kokate CK. In: *Practical Pharmacognosy, Preliminary Phytochemical Screening*, first ed., Vallabh Prakashan, New Delhi, 1986; 111.
14. Dhawan D, Bandhu HK, Singh A. Nagpal, Effect of D-400 (a herbal formulation) on the regulation of glucose metabolism in diabetic rats. *Indian Journal of Pharmacology* 1996; 28: 224.
15. Sharma SR, Dwivedi SK, Swarup D. Hypoglycemic, antihyperglycemic and hypolipidemic activity of *Caesalpinia bonducella* seeds in rats. *Journal of Ethnopharmacology* 1997; 58: 39-44.
16. Babu V, Gangadevi T, Subramoniam A. Antihyperglycemic activity of *Cassia Kleinii* leafextract in glucose fed normal rats and alloxan induced diabetic rats. *Indian J. of Pharmacology* 2002; 34: 409-15.
17. Dash GK, Patro CHP, Maiti AK. A study on the anti-hyperglycemic effect of *Premna Corymbosa* Rottl.roots. *Journal of Natural remedies* 2005; 5: 31-34.
18. Bairy KL, Sharma A, Shalini A. Evaluation of hypoglycemic, hypolipidemic and hepatic glycogen raising effect of *Syzygium Malaccense* upon streptozotocin induced diabetic rats. *Journal of Natural remedies* 2005; 5: 46-51.
19. Hatapakki BC, Suresh HM, Bhoomannavar V, Shivakumar SI. Effect of *Cassia Auriculata* Linn flowers against Alloxan-induced diabetes in rats. *A Journal of Natural remedies* 2005; 5: 132-36.
20. Bhat ZA, Ansari SH, Mukhtar HM. Anti-hyperglycemic activity of the alcoholic extract of *Aralia Cachemirica* Decne roots. *Journal of Natural remedies* 2005; 5:160-62.
21. Szkudelski T. The mechanism of Alloxan and Streptozotocin action in B cells of the rat pancreas. *Physiol Res* 2001; 50: 537-46.
22. Yadav SB, TripathiV, SinghRK, PandeyHP. Antioxidantactivityof *Cuscuta reflexa* stem. *IndianJPharmSci* 2000; 62: 477-78.

23. Glombitza KW, Mahran GH, Mirhom YW. Hypoglycaemic and antihyperglycaemic effects of *Zizyphus spina-christi* in rats. *Planta Med* 1994; 60: 244-47.
24. Kamel MS, Ohtani K, Kurokawa T. Studies on *Balanites aegyptiaca* fruits, an antidiabetic Egyptian folk medicine. *Chem Pharm Bull* 1991; 39: 1229-33.
25. Ibrahim N, el-Eraky W, el-Gengaihi S, Shalaby AS. Chemical and biological evaluation of proteins and mucilage from roots and seeds of *Glossostemon bruguieri* Desf. (Moghat). *Plant Foods Hum Nutr* 1997; 50: 55-51.
26. Akhtar MS, Iqbal J. Evaluation of the hypoglycaemic effect of *Achyranthes aspera* in normal and alloxandiabetic rabbits. *J Ethnopharmacol* 1991; 1: 49-57.
27. Temme Eh, Vaqn HPG, Schouten EG, Kesteloot H. Effect of plant sterol-enriched spread on serum lipids and lipoproteins in mildly hypercholesterolaemic subjects. *Acta Cardiology* 2002; 57: 111-15.
28. Bainton D, Miller NE, Botton CH, Yarnell JWG, Suretman PM, Baker IA. Plasma triglycerides and high density lipoprotein cholesterol as predictors of ischemic heart disease in British man. *Br Heart J* 1992; 68: 60-66.
29. El-harzi MA, Warsy AS. Evaluation of serum cholesterol and triglyceride level in 1-6- year -old Saudi children. *J Trop Pediatr* 2001; 47: 181-85.
30. Ravi K, Rajasekaran S, Subramanian S. Antihyperlipidemia effect of *Eugenia Jambolana* seed kernel on streptozotocin induced diabetes in rats. *Food chem. Toxicol* 2005; 43: 1433-39.
31. Leontowicz H, Gorinstein S, Lojek A, Leontowicz M, Ciz M, Soliva- Fortuny R, *et al.* Comparative content of some bioactive compounds in apples, peaches and pears and their influence on lipids and antioxidant capacity in rats. *J Nutr Biochem.* 2002; 13: 603-10.
32. Kimura Y, Okuda H. Effects of active compounds isolated from *Angelicashikokiana* on lipid metabolism in fat cells. *J Ethnopharmacol.* 1989; 25: 269-80.
33. Ogawa H, Nakamura R, Baba K. Beneficial effect of laserpitin, a coumarin compound from *Angelica keiskei*, on lipid metabolism in stroke-prone spontaneously hypertensive rats. *Clin Exp Pharmacol Physiol* 2005; 32: 1104-09.